CLINICAL TRIALS PROFILE FOR SPRINTEC
✉ Email this page to a colleague
All Clinical Trials for SPRINTEC
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01475513 ↗ | Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women | Completed | American Heart Association | Phase 4 | 2011-11-01 | Birth control pills are the most commonly used method of birth control. The purpose of this research study is to examine whether birth control pills change heart disease risk and how the body handles blood sugar when given to different women. |
| NCT01475513 ↗ | Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women | Completed | Virginia Commonwealth University | Phase 4 | 2011-11-01 | Birth control pills are the most commonly used method of birth control. The purpose of this research study is to examine whether birth control pills change heart disease risk and how the body handles blood sugar when given to different women. |
| NCT02144246 ↗ | Contraceptive Hormones and Women With Cystic Fibrosis | Terminated | Society of Family Planning | Phase 1 | 2014-05-01 | Primary Objective Our primary objective in this study is to evaluate satisfaction of hormonal contraception in this sample of women and to evaluate the impact that this hormonal contraceptive has on cystic fibrosis (CF) disease in women with regular menstrual cycles accompanied by cyclic exacerbations. We hypothesize: 1a) women with CF who perceive an overall benefit of hormonal contraception will be more satisfied than women with CF who do not perceive a benefit, 1b) women with CF who have cyclic exacerbations will have decreased Pseudomonas aeruginosa mucoidy conversion while using hormonal contraception, 1c) women with CF who have cyclic exacerbations will have improved patient-reported quality of life indices while on hormonal contraception, and 1d) women with CF who have cyclic exacerbations will have improvement in pulmonary function tests while on hormonal contraception. Secondary Objective We plan to secondarily evaluate the cervical mucus of women with CF at the time of ovulation and compare it to that of healthy controls. We hypothesize that women with CF have ovulatory cervical mucus similar to healthy peers. |
| NCT02144246 ↗ | Contraceptive Hormones and Women With Cystic Fibrosis | Terminated | University of Pennsylvania | Phase 1 | 2014-05-01 | Primary Objective Our primary objective in this study is to evaluate satisfaction of hormonal contraception in this sample of women and to evaluate the impact that this hormonal contraceptive has on cystic fibrosis (CF) disease in women with regular menstrual cycles accompanied by cyclic exacerbations. We hypothesize: 1a) women with CF who perceive an overall benefit of hormonal contraception will be more satisfied than women with CF who do not perceive a benefit, 1b) women with CF who have cyclic exacerbations will have decreased Pseudomonas aeruginosa mucoidy conversion while using hormonal contraception, 1c) women with CF who have cyclic exacerbations will have improved patient-reported quality of life indices while on hormonal contraception, and 1d) women with CF who have cyclic exacerbations will have improvement in pulmonary function tests while on hormonal contraception. Secondary Objective We plan to secondarily evaluate the cervical mucus of women with CF at the time of ovulation and compare it to that of healthy controls. We hypothesize that women with CF have ovulatory cervical mucus similar to healthy peers. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SPRINTEC
Condition Name
Clinical Trial Locations for SPRINTEC
Trials by Country
Clinical Trial Progress for SPRINTEC
Clinical Trial Phase
Clinical Trial Sponsors for SPRINTEC
Sponsor Name
